Here's how NATURE.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

NATURE . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Nature.com Make Money
  6. How Much Does Nature.com Make
  7. Keywords
  8. Topics
  9. Questions
  10. Schema
  11. Social Networks
  12. External Links
  13. Analytics And Tracking
  14. Libraries
  15. Hosting Providers

We are analyzing https://www.nature.com/articles/6691522.

Title:
C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance | British Journal of Cancer
Description:
Data from basic research suggests that amplification of the proto-oncogene c-myc is important in breast cancer pathogenesis, but its frequency of amplification and prognostic relevance in human studies have been inconsistent. In an effort to clarify the clinical significance of c-myc amplification in breast cancer, we conducted a comprehensive literature search and a meta-analysis in which 29 studies were evaluated. The weighted average frequency of c-myc amplification in breast tumours was 15.7% (95% CI = 12.5–18.8%), although estimates in individual studies exhibited significant heterogeneity, P<0.0001. C-myc amplification exhibited significant but weak associations with tumour grade (RR = 1.61), lymph-node metastasis (RR = 1.24), negative progesterone receptor status (RR = 1.27), and postmenopausal status (RR = 0.82). Amplification was significantly associated with risk of relapse and death, with pooled estimates RR = 2.05 (95% CI = 1.51–2.78) and RR = 1.74 (95% CI = 1.27–2.39), respectively. This effect did not appear to be merely a surrogate for other prognostic factors. These results suggest that c-myc amplification is relatively common in breast cancer and may provide independent prognostic information. More rigorous studies with consistent methodology are required to validate this association, and to investigate its potential as a molecular predictor of specific therapy response. © 2000 Cancer Research Campaign http://www.bjcancer.com
Website Age:
30 years and 10 months (reg. 1994-08-11).

Matching Content Categories {📚}

  • Education
  • Health & Fitness
  • Non-Profit & Charity

Content Management System {📝}

What CMS is nature.com built with?

Custom-built

No common CMS systems were detected on Nature.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of nature.com audience?

🌆 Monumental Traffic: 20M - 50M visitors per month


Based on our best estimate, this website will receive around 42,555,829 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Nature.com Make Money? {💸}


Display Ads {🎯}


The website utilizes display ads within its content to generate revenue. Check the next section for further revenue estimates.

Ads are managed by yourbow.com. Particular relationships are as follows:

Direct Advertisers (10)
google.com, pmc.com, doceree.com, yourbow.com, audienciad.com, onlinemediasolutions.com, advibe.media, aps.amazon.com, getmediamx.com, onomagic.com

Reseller Advertisers (38)
conversantmedia.com, rubiconproject.com, pubmatic.com, appnexus.com, openx.com, smartadserver.com, lijit.com, sharethrough.com, video.unrulymedia.com, google.com, yahoo.com, triplelift.com, onetag.com, sonobi.com, contextweb.com, 33across.com, indexexchange.com, media.net, themediagrid.com, adform.com, richaudience.com, sovrn.com, improvedigital.com, freewheel.tv, smaato.com, yieldmo.com, amxrtb.com, adyoulike.com, adpone.com, criteo.com, smilewanted.com, 152media.info, e-planning.net, smartyads.com, loopme.com, opera.com, mediafuse.com, betweendigital.com

How Much Does Nature.com Make? {💰}


Display Ads {🎯}

$536,300 per month
Our estimates place Nature.com's monthly online earnings from display ads at $357,511 to $983,155.

Keywords {🔍}

cancer, google, scholar, breast, pubmed, article, cas, cmyc, amplification, human, res, nature, prognostic, oncogene, cerbb, cell, research, int, carcinomas, content, tumor, central, cookies, open, metaanalysis, protooncogene, clinical, primary, privacy, analysis, data, access, studies, patients, gene, oncogenes, genes, genetic, expression, information, journal, nass, dickson, trock, tumour, independent, publication, chromosomal, carcinoma, van,

Topics {✒️}

nature portfolio privacy policy c-erbb-2/cerba coamplification indicative advertising nature 299 nature 306 nature basic research suggests social media cancer research 0/ reprints epidemiologic research chromosome 1p32-pter controls c-erbb-2/neu proto-oncogenes node-negative breast carcinomas c-ha-ras protooncogenes normal development proto-oncogene c-myc c-myc proto-oncogene poor short-term prognosis c-myc proto-oncogenes c-myc oncogene amplification c-myc gene amplification permissions personal data development hormone receptor+ve data protection high cell kinetics lymph-node metastasis lymph node metastasis c-myc genes human breast cancer human breast carcinomas her2/neu amplification privacy �statistically significant’ clinically breast cancer patients c-myc oncogene c-myc protooncogene human breast tumors myc family genes primary breast cancer c-myc amplification c-myc gene breast cancer pathogenesis breast cancer imprints breast cancer depends explore content similar content

Questions {❓}

  • Hayes DF, Trock B and Harris AL (1998) Assessing the clinical impact of prognostic factors: when is ‘statistically significant’ clinically useful?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance
         description:Data from basic research suggests that amplification of the proto-oncogene c-myc is important in breast cancer pathogenesis, but its frequency of amplification and prognostic relevance in human studies have been inconsistent. In an effort to clarify the clinical significance of c-myc amplification in breast cancer, we conducted a comprehensive literature search and a meta-analysis in which 29 studies were evaluated. The weighted average frequency of c-myc amplification in breast tumours was 15.7% (95% CI = 12.5–18.8%), although estimates in individual studies exhibited significant heterogeneity, P<0.0001. C-myc amplification exhibited significant but weak associations with tumour grade (RR = 1.61), lymph-node metastasis (RR = 1.24), negative progesterone receptor status (RR = 1.27), and postmenopausal status (RR = 0.82). Amplification was significantly associated with risk of relapse and death, with pooled estimates RR = 2.05 (95% CI = 1.51–2.78) and RR = 1.74 (95% CI = 1.27–2.39), respectively. This effect did not appear to be merely a surrogate for other prognostic factors. These results suggest that c-myc amplification is relatively common in breast cancer and may provide independent prognostic information. More rigorous studies with consistent methodology are required to validate this association, and to investigate its potential as a molecular predictor of specific therapy response. © 2000 Cancer Research Campaign http://www.bjcancer.com
         datePublished:2000-12-05T00:00:00Z
         dateModified:2011-11-16T00:00:00Z
         pageStart:1688
         pageEnd:1695
         sameAs:https://doi.org/10.1054/bjoc.2000.1522
         keywords:
             c-myc
            amplification
            breast cancer
            prognostic markers
            meta-analysis
            Biomedicine
            general
            Cancer Research
            Epidemiology
            Molecular Medicine
            Oncology
            Drug Resistance
         image:
         isPartOf:
            name:British Journal of Cancer
            issn:
               1532-1827
               0007-0920
            volumeNumber:83
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Nature Publishing Group UK
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:S L Deming
               affiliation:
                     name:Georgetown University, Wisconsin Avenue
                     address:
                        name:Department of Oncology and Lombardi Cancer Center, Georgetown University, Wisconsin Avenue, Washington
                        type:PostalAddress
                     type:Organization
               type:Person
               name:S J Nass
               affiliation:
                     name:Oncology Center, The Johns Hopkins University School of Medicine
                     address:
                        name:Oncology Center, The Johns Hopkins University School of Medicine, Baltimore, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:R B Dickson
               affiliation:
                     name:Georgetown University, Wisconsin Avenue
                     address:
                        name:Department of Oncology and Lombardi Cancer Center, Georgetown University, Wisconsin Avenue, Washington
                        type:PostalAddress
                     type:Organization
               type:Person
               name:B J Trock
               affiliation:
                     name:Georgetown University, Wisconsin Avenue
                     address:
                        name:Department of Oncology and Lombardi Cancer Center, Georgetown University, Wisconsin Avenue, Washington
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance
      description:Data from basic research suggests that amplification of the proto-oncogene c-myc is important in breast cancer pathogenesis, but its frequency of amplification and prognostic relevance in human studies have been inconsistent. In an effort to clarify the clinical significance of c-myc amplification in breast cancer, we conducted a comprehensive literature search and a meta-analysis in which 29 studies were evaluated. The weighted average frequency of c-myc amplification in breast tumours was 15.7% (95% CI = 12.5–18.8%), although estimates in individual studies exhibited significant heterogeneity, P<0.0001. C-myc amplification exhibited significant but weak associations with tumour grade (RR = 1.61), lymph-node metastasis (RR = 1.24), negative progesterone receptor status (RR = 1.27), and postmenopausal status (RR = 0.82). Amplification was significantly associated with risk of relapse and death, with pooled estimates RR = 2.05 (95% CI = 1.51–2.78) and RR = 1.74 (95% CI = 1.27–2.39), respectively. This effect did not appear to be merely a surrogate for other prognostic factors. These results suggest that c-myc amplification is relatively common in breast cancer and may provide independent prognostic information. More rigorous studies with consistent methodology are required to validate this association, and to investigate its potential as a molecular predictor of specific therapy response. © 2000 Cancer Research Campaign http://www.bjcancer.com
      datePublished:2000-12-05T00:00:00Z
      dateModified:2011-11-16T00:00:00Z
      pageStart:1688
      pageEnd:1695
      sameAs:https://doi.org/10.1054/bjoc.2000.1522
      keywords:
          c-myc
         amplification
         breast cancer
         prognostic markers
         meta-analysis
         Biomedicine
         general
         Cancer Research
         Epidemiology
         Molecular Medicine
         Oncology
         Drug Resistance
      image:
      isPartOf:
         name:British Journal of Cancer
         issn:
            1532-1827
            0007-0920
         volumeNumber:83
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Nature Publishing Group UK
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:S L Deming
            affiliation:
                  name:Georgetown University, Wisconsin Avenue
                  address:
                     name:Department of Oncology and Lombardi Cancer Center, Georgetown University, Wisconsin Avenue, Washington
                     type:PostalAddress
                  type:Organization
            type:Person
            name:S J Nass
            affiliation:
                  name:Oncology Center, The Johns Hopkins University School of Medicine
                  address:
                     name:Oncology Center, The Johns Hopkins University School of Medicine, Baltimore, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:R B Dickson
            affiliation:
                  name:Georgetown University, Wisconsin Avenue
                  address:
                     name:Department of Oncology and Lombardi Cancer Center, Georgetown University, Wisconsin Avenue, Washington
                     type:PostalAddress
                  type:Organization
            type:Person
            name:B J Trock
            affiliation:
                  name:Georgetown University, Wisconsin Avenue
                  address:
                     name:Department of Oncology and Lombardi Cancer Center, Georgetown University, Wisconsin Avenue, Washington
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:British Journal of Cancer
      issn:
         1532-1827
         0007-0920
      volumeNumber:83
Organization:
      name:Nature Publishing Group UK
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Georgetown University, Wisconsin Avenue
      address:
         name:Department of Oncology and Lombardi Cancer Center, Georgetown University, Wisconsin Avenue, Washington
         type:PostalAddress
      name:Oncology Center, The Johns Hopkins University School of Medicine
      address:
         name:Oncology Center, The Johns Hopkins University School of Medicine, Baltimore, USA
         type:PostalAddress
      name:Georgetown University, Wisconsin Avenue
      address:
         name:Department of Oncology and Lombardi Cancer Center, Georgetown University, Wisconsin Avenue, Washington
         type:PostalAddress
      name:Georgetown University, Wisconsin Avenue
      address:
         name:Department of Oncology and Lombardi Cancer Center, Georgetown University, Wisconsin Avenue, Washington
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:S L Deming
      affiliation:
            name:Georgetown University, Wisconsin Avenue
            address:
               name:Department of Oncology and Lombardi Cancer Center, Georgetown University, Wisconsin Avenue, Washington
               type:PostalAddress
            type:Organization
      name:S J Nass
      affiliation:
            name:Oncology Center, The Johns Hopkins University School of Medicine
            address:
               name:Oncology Center, The Johns Hopkins University School of Medicine, Baltimore, USA
               type:PostalAddress
            type:Organization
      name:R B Dickson
      affiliation:
            name:Georgetown University, Wisconsin Avenue
            address:
               name:Department of Oncology and Lombardi Cancer Center, Georgetown University, Wisconsin Avenue, Washington
               type:PostalAddress
            type:Organization
      name:B J Trock
      affiliation:
            name:Georgetown University, Wisconsin Avenue
            address:
               name:Department of Oncology and Lombardi Cancer Center, Georgetown University, Wisconsin Avenue, Washington
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Oncology and Lombardi Cancer Center, Georgetown University, Wisconsin Avenue, Washington
      name:Oncology Center, The Johns Hopkins University School of Medicine, Baltimore, USA
      name:Department of Oncology and Lombardi Cancer Center, Georgetown University, Wisconsin Avenue, Washington
      name:Department of Oncology and Lombardi Cancer Center, Georgetown University, Wisconsin Avenue, Washington

Social Networks {👍}(1)

External Links {🔗}(155)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Prism.js
  • Zoom.js

Emails and Hosting {✉️}

Mail Servers:

  • mxa-002c5801.gslb.pphosted.com
  • mxb-002c5801.gslb.pphosted.com

Name Servers:

  • pdns1.ultradns.net
  • pdns2.ultradns.net
  • pdns3.ultradns.org
  • pdns4.ultradns.org
  • pdns5.ultradns.info
  • pdns6.ultradns.co.uk
4.6s.